Renal Transplant Rejection Clinical Trial
Official title:
Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function & Lymphocytes Function
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant. The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil(MMF)/Cellcept® and tacrolimus(TAC)/Prograf® (Group 1) or mycophenolate mofetil(MMF)/Cellcept® and sirolimus/Rapamune® (Group 2) impacts the incidence of acute cellular rejection in post kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.
For this research study, between 6 and 24 Months post-transplant, we plan to prospectively
randomize 2:1 renal transplant patients to either:
- Substitute tacrolimus (TAC) with sirolimus and continue mycophenolate mofetil (MMF) or
- Continue with tacrolimus (TAC) and mycophenolate mofetil (MMF)
A total of 400 patients are expected to be screened for the randomization. We expect to
randomize 275 renal transplant patients into this protocol (275 donors to be recruited).
The following data will be collected at the time of randomization:
Recipient demographics: (i) age at transplantation, (ii) sex, and (iii) race.
Clinical history: (i) causes of end-stage renal disease, and (ii) past medical history.
Transplant related information: (i) donor age, (ii) cadaveric versus living kidney
transplant, (iii) histocompatibility and cross match data, (iv) viral serology, (v) history
of acute rejection and delayed graft function, (vi) use of induction therapy and
immunosuppressants, (vii) use of ACEI and/or ARB, and (viii) level of renal allograft
function-estimated GFR (e-GFR(12) using MDRD formula, proteinuria.
Peripheral blood leukocytes will be obtained from renal transplant recipients for baseline
(prior to randomization) lymphocytes functional activity and characterization of lymphocytes
subpopulations by flow cytometry analysis.
Peripheral donor leukocytes (from living donor patients) will also be obtained at the time of
randomization. These donor leukocytes will be used as stimulator cells to study the
functional activity of the recipient's lymphocytes function.
The recipients assigned to continue with tacrolimus and MMF will be routinely followed at the
outpatient Comprehensive Transplant Center (CTC) with monthly labs. In addition to labs at
baseline pre-randomization, 6, 12 and 24 Months post-randomization, peripheral blood
leukocytes will be obtained to study lymphocytes functional activity and to characterize
lymphocytes subpopulations by flow cytometry analysis.
Post randomization: The recipients assigned to switch from tacrolimus to sirolimus and
continue with MMF will be routinely followed at the CTC with monthly labs. During the period
of conversion from tacrolimus to sirolimus, weekly labs will be obtained to monitor renal
function and bone marrow function. In addition to labs at baseline pre-randomization, 6, 12
and 24 Months post-randomization, peripheral blood leukocytes will be obtained to study
lymphocytes functional activity to characterize lymphocytes subpopulations by flow cytometry
analysis. Urine will be collected to assess tubular toxicity by evaluating urinary
biomarkers.
Both groups of patients will be followed for 2 years post-randomization. In addition to
monitoring renal allograft function, we will evaluate the incidence of acute rejection,
patient and graft survival, impact of CI conversion on the lipid profile, incidence of
hypertension, malignancies, opportunistic infections, and post-transplant diabetes mellitus
(DM). For those willing to undergo an optional kidney biopsy, one will be performed at the
end of the second year in order to evaluate renal allograft pathology and renal allograft
tissue gene expression profiles of the two groups.
With the peripheral leukocytes obtained at baseline prior to randomization and at 6, 12 and
24 Months post-randomization, we will investigate possible modifications of lymphocytes
function and the lymphocytes subpopulations that might have occurred as a consequence of the
switch from tacrolimus to sirolimus.
Obtaining renal allograft tissue samples at 24 months post randomization can have potential
important ramifications to help explain the mechanisms of fibrosis and tubular atrophy
typically associated with CI and the role of CI elimination with the substitution of
sirolimus (SRL). All data will then be analyzed comparing gene expression profiles of
peripheral blood (Pax gene tubes are routinely collected at the different time points as part
of the original study). Based on power analysis, we will perform 24 months post randomization
biopsies in 70% of the total subjects enrolled in the study (approximately 46 subjects from
the tacrolimus/MMF group and approximately 93 subjects from the sirolimus/MMF group).
We plan to obtain renal allograft biopsies at 24 Months for those that consent for this
additional biopsy. This will be compared to the standard of care 12 months post-transplant
biopsy to allow us to address the effect of immunosuppressive modifications on renal
allograft pathology at 24 months post randomization. Renal allograft biopsies will also be
stored in RNA later to further extend our knowledge on the effect of CI free
immunosuppression on gene expression profiles.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03140514 -
Urine CXCL10 Chemokine Monitoring Post-renal Transplant
|
N/A | |
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Active, not recruiting |
NCT02409940 -
To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT02377193 -
Simulect Versus ATG in Sensitized Renal Transplant Patient
|
Phase 4 | |
Completed |
NCT00771745 -
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05385432 -
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
|
Phase 3 | |
Completed |
NCT01953120 -
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
|
Phase 4 | |
Terminated |
NCT01324934 -
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
|
Phase 3 | |
Terminated |
NCT00983645 -
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
|
Phase 4 | |
Active, not recruiting |
NCT04530630 -
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
|
Phase 4 | |
Recruiting |
NCT03707262 -
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
|
Phase 1/Phase 2 | |
Completed |
NCT02006108 -
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
|
N/A | |
Recruiting |
NCT03991780 -
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
|
Phase 1/Phase 2 | |
Completed |
NCT02733029 -
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
|
Phase 2 | |
Active, not recruiting |
NCT02057965 -
Mesenchymal Stromal Cell Therapy in Renal Recipients
|
Phase 2 | |
Completed |
NCT00658073 -
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
|
N/A | |
Terminated |
NCT03646344 -
Heme Arginate in Transplantation Study
|
Phase 3 | |
Completed |
NCT02866682 -
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06438107 -
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
|
||
Completed |
NCT02500251 -
Belimumab Impacting Transplant Eligibility
|
Phase 1/Phase 2 |